hpski's Comments RSS Syndication from SeekingAlpha.com http://seekingalpha.comuser/64635/comments http://seekingalpha.com/article/163691-which-pfizer-wyeth-sites-will-shut-down?source=feed#comment-696371 696371

On Sep 29 11:20 AM Trane250 wrote:

> The bottom line is what motivates Pfizer. To hell with anything else.
>
>
> "After several years of eliminating jobs that once totaled 3,600
> at that company's [Warner-Lambert's] Ann Arbor, Mich., facility,
> Pfizer announced its closing in January 2007. Among those put out
> of work was Bob Sliskovic, a scientist credited with developing Lipitor."]]> Tue, 29 Sep 2009 22:48:31 -0400

On Sep 29 11:20 AM Trane250 wrote:

> The bottom line is what motivates Pfizer. To hell with anything else.
>
>
> "After several years of eliminating jobs that once totaled 3,600
> at that company's [Warner-Lambert's] Ann Arbor, Mich., facility,
> Pfizer announced its closing in January 2007. Among those put out
> of work was Bob Sliskovic, a scientist credited with developing Lipitor."]]> http://seekingalpha.com/article/151854-intuitive-surgical-accident-prone-for-profits?source=feed#comment-607035 607035
Thanks in advance!]]> Wed, 29 Jul 2009 15:21:37 -0400
Thanks in advance!]]> http://seekingalpha.com/article/150019-extreme-fda-trades-20-stocks-under-5-bucks?source=feed#comment-598533 598533 Wed, 22 Jul 2009 16:54:06 -0400 http://seekingalpha.com/article/149269-housing-semi-panic-in-orange-county?source=feed#comment-591891 591891 Fri, 17 Jul 2009 10:25:20 -0400 http://seekingalpha.com/article/148415-will-the-democrats-massive-borrowing-and-spending-binge-kill-the-u-s-economy?source=feed#comment-587886 587886 Tue, 14 Jul 2009 14:12:58 -0400 http://seekingalpha.com/article/139788-top-biotech-picks-for-asco-2009-part-ii?source=feed#comment-521940 521940
OFATUMUMAB AND R1507 DATA TO BE PRESENTED AT ASCO

Copenhagen, Denmark; May 11, 2009 – Genmab A/S (OMX: GEN) announced today that data from the ofatumumab and R1507 development programs will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29-June 2 in Orlando, Florida.



Ofatumumab – Poster session, May 30 from 8AM to 12PM EDT

Abstract # 7044 Ofatumumab, a novel CD20 mAb, is active regardless of prior rituximab exposure in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia (CLL).



Ofatumumab – Poster session, May 30 from 8AM to 12PM EDT

Abstract # 7043 Clinical improvement with a novel CD20 mAb, ofatumumab, in fludarabine-refractory chronic lymphocytic leukemia (CLL) also refractory to alemtuzumab or with bulky lymphadenopathy.



R1507 – Oral presentation, June 1 at 3PM EDT

Abstract # 10503 A SARC global collaborative Phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas.



R1507 – Poster session, May 30, 2PM to 6PM EDT

Abstract # 8095 Expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507)



The full abstracts will be available at asco.org on May 14, 2009. ]]> Thu, 28 May 2009 17:02:36 -0400
OFATUMUMAB AND R1507 DATA TO BE PRESENTED AT ASCO

Copenhagen, Denmark; May 11, 2009 – Genmab A/S (OMX: GEN) announced today that data from the ofatumumab and R1507 development programs will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29-June 2 in Orlando, Florida.



Ofatumumab – Poster session, May 30 from 8AM to 12PM EDT

Abstract # 7044 Ofatumumab, a novel CD20 mAb, is active regardless of prior rituximab exposure in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia (CLL).



Ofatumumab – Poster session, May 30 from 8AM to 12PM EDT

Abstract # 7043 Clinical improvement with a novel CD20 mAb, ofatumumab, in fludarabine-refractory chronic lymphocytic leukemia (CLL) also refractory to alemtuzumab or with bulky lymphadenopathy.



R1507 – Oral presentation, June 1 at 3PM EDT

Abstract # 10503 A SARC global collaborative Phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas.



R1507 – Poster session, May 30, 2PM to 6PM EDT

Abstract # 8095 Expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507)



The full abstracts will be available at asco.org on May 14, 2009. ]]> http://seekingalpha.com/article/139788-top-biotech-picks-for-asco-2009-part-ii?source=feed#comment-521920 521920
FDA Advisory Committee to Review Arzerra(TM) (Ofatumumab)
11:05a ET May 4, 2009 (GlobeNewswire)

Genmab A/S (OMX:GEN) announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will hold a meeting on May 29, 2009 to review the Arzerra(TM) (ofatumumab) Biologics License Application (BLA) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received prior therapy.

Genmab and GlaxoSmithKline submitted the BLA in January 2009 and announced that the FDA accepted it for review in April 2009. The FDA has granted ofatumumab priority review status. ]]> Thu, 28 May 2009 16:47:39 -0400
FDA Advisory Committee to Review Arzerra(TM) (Ofatumumab)
11:05a ET May 4, 2009 (GlobeNewswire)

Genmab A/S (OMX:GEN) announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will hold a meeting on May 29, 2009 to review the Arzerra(TM) (ofatumumab) Biologics License Application (BLA) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received prior therapy.

Genmab and GlaxoSmithKline submitted the BLA in January 2009 and announced that the FDA accepted it for review in April 2009. The FDA has granted ofatumumab priority review status. ]]> http://seekingalpha.com/article/104971-investing-in-wind-energy-when-will-growth-peak?source=feed#comment-302232 302232 Mon, 10 Nov 2008 15:07:03 -0500 http://seekingalpha.com/article/100191-chuck-schumer-the-new-chairman-of-the-board?source=feed#comment-283940 283940 Thu, 16 Oct 2008 15:12:27 -0400 http://seekingalpha.com/article/97936-for-bargain-hunting-in-a-bear-market-look-at-india?source=feed#comment-270418 270418 Wed, 01 Oct 2008 11:05:40 -0400 http://seekingalpha.com/article/97291-solar-energy-help-is-on-the-way?source=feed#comment-266440 266440 Fri, 26 Sep 2008 18:04:12 -0400 http://seekingalpha.com/article/84424-solar-wafer-prices-on-the-rise-again?source=feed#comment-203377 203377
MEMC and Tainergy Announce $3 Billion+ Solar Wafer Supply Contract
8:02a ET July 10, 2008 (PR NewsWire)

MEMC Electronic Materials, Inc. (NYSE: WFR) and Tainergy Tech Co., Ltd. of Taiwan announced today that they have executed a definitive agreement for MEMC to supply solar wafers to Tainergy. ]]> Fri, 11 Jul 2008 18:34:31 -0400
MEMC and Tainergy Announce $3 Billion+ Solar Wafer Supply Contract
8:02a ET July 10, 2008 (PR NewsWire)

MEMC Electronic Materials, Inc. (NYSE: WFR) and Tainergy Tech Co., Ltd. of Taiwan announced today that they have executed a definitive agreement for MEMC to supply solar wafers to Tainergy. ]]> http://seekingalpha.com/article/81043-dendreon-s-provenge-government-agencies-play-hide-and-seek-with-facts?source=feed#comment-184399 184399 Thu, 12 Jun 2008 14:30:42 -0400 http://seekingalpha.com/article/67990-inhaled-insulin-one-giant-leap-for-mannkind?source=feed#comment-125174 125174
Thanks in advance]]> Tue, 11 Mar 2008 13:10:50 -0400
Thanks in advance]]> http://seekingalpha.com/article/67995-can-we-bury-the-middle-class-income-myths?source=feed#comment-125168 125168 Tue, 11 Mar 2008 13:01:01 -0400 http://seekingalpha.com/article/61741-a-brief-history-of-rogue-traders?source=feed#comment-113244 113244 Mon, 28 Jan 2008 11:48:21 -0500 http://seekingalpha.com/article/56236-time-to-buy-molecular-diagnostics-company-cepheid?source=feed#comment-104215 104215 Wed, 05 Dec 2007 17:49:48 -0500 http://seekingalpha.com/article/53470-bernanke-economic-growth-won-t-last?source=feed#comment-101461 101461
1. Don't fight the Fed - look for oversold situations in great companies immersing themselves in global markets.
2. Every day I get unsolicited mail from banks, mortgage companies, begging me to refinance, open a ELC, write teaser rate checks against CC accounts, car lease specials, etc. I haven't had "earned income" for 2 years. My take on this, merged with watching GE's CEO on Charlie Rose last night, is that there is still plenty of liquidity - the "credit crisis' is basically the ugly ducklings in the secondary mortgage security market being thrown out of the nest. ]]> Fri, 09 Nov 2007 14:39:51 -0500
1. Don't fight the Fed - look for oversold situations in great companies immersing themselves in global markets.
2. Every day I get unsolicited mail from banks, mortgage companies, begging me to refinance, open a ELC, write teaser rate checks against CC accounts, car lease specials, etc. I haven't had "earned income" for 2 years. My take on this, merged with watching GE's CEO on Charlie Rose last night, is that there is still plenty of liquidity - the "credit crisis' is basically the ugly ducklings in the secondary mortgage security market being thrown out of the nest. ]]> http://seekingalpha.com/article/51756-alseres-pharmaceuticals-undervalued-in-conservative-dcf-calculation?source=feed#comment-100250 100250
Disclosure: I have no position in ALSE, am long DNDN, EXEL, CEGE, AGEN, recommend ACAD under $15 ]]> Mon, 29 Oct 2007 19:18:18 -0400
Disclosure: I have no position in ALSE, am long DNDN, EXEL, CEGE, AGEN, recommend ACAD under $15 ]]> http://seekingalpha.com/article/46333-more-on-pork-china-and-smithfield-foods?source=feed#comment-95206 95206 Wed, 05 Sep 2007 14:35:38 -0400 http://seekingalpha.com/article/46081-did-bernanke-really-just-suggest-creative-mortgages?source=feed#comment-94885 94885 Fri, 31 Aug 2007 13:37:07 -0400 http://seekingalpha.com/article/45912-the-wolf-of-wall-street-not-so-hilarious?source=feed#comment-94739 94739 Wed, 29 Aug 2007 13:28:03 -0400 http://seekingalpha.com/article/45658-bank-of-america-last-man-standing?source=feed#comment-94735 94735 Wed, 29 Aug 2007 13:06:13 -0400 http://seekingalpha.com/article/45698-expect-pressure-on-myriad-genetics-following-trial-news?source=feed#comment-94595 94595 Mon, 27 Aug 2007 13:26:07 -0400 http://seekingalpha.com/article/45535-is-antigenics-a-good-buy-right-now?source=feed#comment-94537 94537
Disclosure: I periodically own AGEN, CEGE, DNDN, am long EXEL]]> Fri, 24 Aug 2007 14:41:15 -0400
Disclosure: I periodically own AGEN, CEGE, DNDN, am long EXEL]]> http://seekingalpha.com/article/45391-interest-rate-cut-sleep-it-off-overall-things-look-good?source=feed#comment-94454 94454
Disclosure: I am a biotech investment specialist - incremental interest rate fluctuations pose less risk for me and my clients than phase 2 & 3 clinical trial outcomes, strategic alliances / buyouts and leadership quality.]]> Thu, 23 Aug 2007 21:20:41 -0400
Disclosure: I am a biotech investment specialist - incremental interest rate fluctuations pose less risk for me and my clients than phase 2 & 3 clinical trial outcomes, strategic alliances / buyouts and leadership quality.]]> http://seekingalpha.com/article/41851-northwest-biotherapeutics-stock-may-fade-on-misleading-press-release?source=feed#comment-93509 93509 Sun, 12 Aug 2007 17:56:06 -0400 http://seekingalpha.com/article/44214-the-plunge-protection-team-working-overtime-a-play-by-play?source=feed#comment-93497 93497 Sun, 12 Aug 2007 13:26:47 -0400 http://seekingalpha.com/article/42434-david-fry-s-market-outlook-for-thursday?source=feed#comment-92245 92245
HP]]> Thu, 26 Jul 2007 20:48:03 -0400
HP]]> http://seekingalpha.com/article/39619-american-oriental-bioengineering-stirs-up-controversy?source=feed#comment-89986 89986 Fri, 29 Jun 2007 10:39:30 -0400